- Home
- ZIMV vs CTMX Comparison
ZIMV vs CTMX Comparison
Compare ZIMV & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIMV
- CTMX
- Stock Information
- Founded
- ZIMV 2021
- CTMX 2008
- Country
- ZIMV United States
- CTMX United States
- Employees
- ZIMV N/A
- CTMX N/A
- Industry
- ZIMV Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- ZIMV Health Care
- CTMX Health Care
- Exchange
- ZIMV Nasdaq
- CTMX Nasdaq
- Market Cap
- ZIMV 532.3M
- CTMX 544.2M
- IPO Year
- ZIMV N/A
- CTMX 2015
- Fundamental
- Price
- ZIMV $18.93
- CTMX $3.31
- Analyst Decision
- ZIMV Hold
- CTMX Strong Buy
- Analyst Count
- ZIMV 3
- CTMX 5
- Target Price
- ZIMV $14.50
- CTMX $5.30
- AVG Volume (30 Days)
- ZIMV 323.0K
- CTMX 4.3M
- Earning Date
- ZIMV 10-29-2025
- CTMX 11-06-2025
- Dividend Yield
- ZIMV N/A
- CTMX N/A
- EPS Growth
- ZIMV N/A
- CTMX 263.20
- EPS
- ZIMV N/A
- CTMX 0.49
- Revenue
- ZIMV $443,402,000.00
- CTMX $141,100,000.00
- Revenue This Year
- ZIMV $2.49
- CTMX N/A
- Revenue Next Year
- ZIMV $1.26
- CTMX N/A
- P/E Ratio
- ZIMV N/A
- CTMX $6.80
- Revenue Growth
- ZIMV N/A
- CTMX 18.01
- 52 Week Low
- ZIMV $8.15
- CTMX $0.40
- 52 Week High
- ZIMV $19.01
- CTMX $3.49
- Technical
- Relative Strength Index (RSI)
- ZIMV 72.82
- CTMX 75.08
- Support Level
- ZIMV $18.87
- CTMX $3.11
- Resistance Level
- ZIMV $18.99
- CTMX $3.39
- Average True Range (ATR)
- ZIMV 0.03
- CTMX 0.24
- MACD
- ZIMV -0.08
- CTMX 0.08
- Stochastic Oscillator
- ZIMV 45.46
- CTMX 88.52
About ZIMV ZimVie Inc.
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.